A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin; Cisplatin; Paclitaxel; Paclitaxel
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
Most Recent Events
- 27 May 2013 Biomarkers information updated
- 24 Mar 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Feb 2007 Quality-of-life results have been published.